Replies to post #1531548 on STOCK GOODIES PLAYS OF THE WEEK

[1~Eye~Jack!!]

~ RGBP = EXACTLY CorRrect! ;-)

Thank-you for that Dr. V & good to see you back herRre! ;-)

Yes, RGBP @ $10+++ & BMSN @ .30+++ is Conservative! ;-) ,,,but We,, "da RGBP/BMSN Crew" arRre Accumulating @ these undervalued PPS's in Both, as they are inter~connected & rRready for da Bla$t-off!! ;-)

Dr. V
http://investorshub.advfn.com/boards/read_msg.aspx?message_id=108538603

These are conservative numbers for the end game, Jack. If you are speaking about FDA approval for Phase 1 trials for either HemaXellerate or dCellVax, then I would agree with your estimates.

Take a look at some of the companies that are in phase 3 and it will blow your mind. Moreover, these stocks that are in the triple digits per share with a similar share structure only have 1 drug in the pipeline!

The strategy that I believe that Dr. Koos is trying to accomplish is simply this. Get approval to begin clinical trials for either, get the price per share up and stay there for at least 90 days, and then file to be up listed on a better exchange, most likely NASDAQ. Yes there are requirements other than price per share, but there are ways around that, especially with biotech stocks that are in clinical trials.

A biotech trading on a better exchange with a chance to treat and or cure breast cancer will go through the roof.

I've been away for a while, but rest assured I not only am still on board the RGBP train, but I keep adding when I can. The doubt and whining on here was getting annoying.

I agree with what you quoted, RGBP is most definitely moving forward and beginning to be transparent in their communications and press releases. Stand by folks and enjoy the ride.

Go BMSN!! b:-)d

[1~Eye~Jack!!]

~ RGBP = New$ Out TODAY! ;-)

http://investorshub.advfn.com/boards/read_msg.aspx?message_id=108544535